Pinpaw′s 5mg Chewable Tablets Pimobendan for Dogs, Pet Health Solution

• Customization: Available
• Varieties: General Disease Prevention Medicine
• Component: Pimobendan
• Model NO.: 5mg Pimobendan Chewable Tablets for Dogs
• Type: The First Class
• Pharmacodynamic Influential Factors: Incompatibility
• Storage Method: Prevent High or LowTemperature
• Veterinary Reg. No.: 180477183
• Transport Package: Bottled
• Specification: 5mg/tablet
• Trademark: pinpaw
• Origin: Changsha
• Production Capacity: 50000 Boxes Per Day

Product Description

Product Description
GENERIC NAME:
Pimobendan Chewable Tablet
MAIN COMPONENT:
Pimobendan
DESCRIPTION:
Delight in the innovation of our light brown, scored tablets, designed with a savory beef flavor to ensure your pet's compliance and satisfaction, blending palatability with function.
PHARMACOLOGICAL EFFECTS:
Pharmacodynamics: Pimobendan stands out as a unique, non-glycoside cardiotonic agent in the veterinary field. As a benzimidazole pyridazinone derivative, this exceptional compound distinguishes itself by enhancing cardiac contractility without sympathomimetic activity, working through increased calcium sensitivity in cardiac fibers and phosphodiesterase (Type III) inhibition, creating a potent vasodilatory effect. In combination with diuretics like furosemide, Pimobendan significantly enhances the quality and longevity of life in canines suffering from dilated cardiomyopathy or heart valve insufficiency. Moreover, when administered as a monotherapy for preclinical, asymptomatic dilated cardiomyopathy in large breed dogs, Pimobendan effectively delays heart failure onset, extends survival, and safeguards against sudden cardiac events.
By skillfully reducing heart volume, Pimobendan addresses preclinical myxomatous mitral valve disease in dogs, marked by a systolic mitral murmur and augmented heart size, delaying symptomatic heart failure or cardiac arrest onset by an average of 15 months, while admirably prolonging total survival by an estimated 170 days.
Pharmacokinetics: After administration, Pimobendan undergoes oxidative demethylation, transforming into a bioactive metabolite that conjugates with sulfate or glucuronide. This compound is predominantly expelled through fecal pathways. Notably, the mean protein binding of Pimobendan and its active metabolite in canine plasma exceeds 90%, highlighting its effective plasma affinity.
A meticulous bioequivalence evaluation was conducted between our product and the RLD Pimobendan Chewable Tablet (Vetmedin^®), affirming that our formulation stands toe-to-toe with the reference, ensuring consistent efficacy and safety.
INDICATIONS:
Pinpaw's 5mg Chewable Tablets are expertly crafted for managing congestive cardiac failure (CCF) in dogs, stemming from heart valve insufficiencies such as mitral and/or tricuspid regurgitation, or dilated cardiomyopathy. Additionally, it is adept at addressing preclinical dilated cardiomyopathy in large dog breeds, diagnosed through echocardiography, or treating preclinical myxomatous mitral valve disease, characterized by a systolic murmur and increased heart size, thereby effectively delaying the progression of CCF's clinical manifestations.
DOSAGE AND ADMINISTRATION:
For optimal results, dosages are meticulously calculated based on Pimobendan, with an oral dose recommendation of 0.25 mg/kg of the dog's body weight to be administered twice daily, ensuring precise and effective treatment.
ADVERSE REACTIONS:
1. In a minimal number of dogs, there may be a minor increase in heart rate and occasional vomiting. These reactions tend to be dose-related and often subside on their own when the dosage is reduced. A few dogs might also experience temporary diarrhea, loss of appetite, or lethargy.
2. Although a direct link to pimobendan is not conclusively proven, some dogs may occasionally show signs of bleeding (such as mucosal or subcutaneous hemorrhage) during treatment. These symptoms generally resolve on their own once the treatment is stopped.
3. In exceedingly rare instances, pimobendan treatment might lead to an increased mitral regurgitation in dogs suffering from mitral valve disease.
PRECAUTIONS:
1. Avoid using this product in conditions like hypertrophic cardiomyopathies or where cardiac output improvement is unattainable due to functional or anatomical reasons (e.g., aortic stenosis). As the product is largely metabolized by the liver, it is not recommended for dogs with severe liver impairment.
2. The product has not undergone testing in Dobermans with asymptomatic dilated cardiomyopathy (DCM) combined with atrial fibrillation or sustained ventricular tachycardia.
3. The product remains untested in asymptomatic cases of myxomatous mitral valve disease where dogs exhibit significant supraventricular or ventricular tachyarrhythmia.
4. Animal studies in rats and rabbits have shown no teratogenic or fetotoxic effects. However, high doses indicated maternotoxic and embryotoxic effects, and it's known that the drug is excreted in milk. Its safety in pregnant or lactating dogs is yet to be evaluated. Use based on a careful risk/benefit analysis by a qualified veterinarian.
5. It's crucial to regularly monitor blood glucose levels in dogs undergoing treatment that have pre-existing diabetes mellitus.
6. For managing the 'preclinical stage' of dilated cardiomyopathy (asymptomatic dogs with increased left ventricular end-systolic and end-diastolic diameters), a thorough cardiac examination, including echocardiography and ambulatory ECG monitoring, is essential for an accurate diagnosis.
7. In preclinical myxomatous mitral valve disease (stage B2 as per ACVIM consensus: asymptomatic with a mitral murmur ≥3/6 paired with myxomatous mitral valve disease-induced cardiomegaly), a detailed cardiac evaluation, combining echocardiography and radiography, is vital for diagnosis.
8. Regular monitoring of cardiac function and morphology is highly recommended for animals receiving pimobendan treatment.
9. Pharmacological research reveals no interplay between pimobendan and the cardiac glycoside ouabain. However, the enhanced cardiac contractility induced by pimobendan is lessened when used alongside calcium antagonists (e.g., verapamil and diltiazem) and beta-blockers.
10. Avoid overdosing. Excessive doses may lead to increased heart rate or vomiting. If such effects occur, reduce the dosage and initiate suitable symptomatic treatment.
11. In healthy Beagle dogs exposed to prolonged high doses (3 to 5 times the recommended amount over 6 months), some showed mitral valve thickening and left ventricular hypertrophy. These effects are attributed to the drug's pharmacodynamics.
12. Ensure this product is kept out of children's reach.
13. Be sure to wash hands thoroughly after handling the product.
14. In case of accidental ingestion, seek medical assistance immediately and provide the product label or package insert to the healthcare professional. Accidental intake, particularly by children, may result in symptoms such as tachycardia, orthostatic hypotension, facial flushing, and headaches.
dbe218a8